Targeting iNOS to increase efficacy of immunotherapies

References

• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016; 14:73; PMID:27151159; http://dx.doi.org/10.1186/s12916-016-0623-510.1186/s12916-016-0623-5
   PubMed Web of Science ®Google Scholar
• Hughes PE, Caenepeel S, Wu LC. Targeted Therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trend Immunol 2016; 37:462-76; PMID:27216414; http://dx.doi.org/10.1016/j.it.2016.04.01010.1016/j.it.2016.04.010
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Investigat 2015; 125:3413-21; PMID:26258412; http://dx.doi.org/10.1172/JCI8000810.1172/JCI80008
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, et al. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep 2016; 6:35848; PMID:27762323; http://dx.doi.org/10.1038/srep3584810.1038/srep35848
   PubMed Web of Science ®Google Scholar
• Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res 2015; 17:25; PMID:25849745; http://dx.doi.org/10.1186/s13058-015-0527-x10.1186/s13058-015-0527-x
   PubMed Web of Science ®Google Scholar
• Cianchi F, Cortesini C, Fantappiè O, Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G, Marzocca C, et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 2003; 162:793-801; PMID:12598314; http://dx.doi.org/10.1016/S0002-9440(10)63876-X10.1016/S0002-9440(10)63876-X
   PubMed Web of Science ®Google Scholar
• Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 2008; 19:133-7; PMID:18472017; http://dx.doi.org/10.1016/j.niox.2008.04.00910.1016/j.niox.2008.04.009
   PubMed Web of Science ®Google Scholar
• Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Inter J Cancer 2006; 119:861-6; PMID:16557582; http://dx.doi.org/10.1002/ijc.2176710.1002/ijc.21767
   PubMed Web of Science ®Google Scholar
• Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 2000; 173:17-26; PMID:10719664; http://dx.doi.org/10.1034/j.1600-065X.2000.917307.x10.1034/j.1600-065X.2000.917307.x
   PubMed Web of Science ®Google Scholar
• Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol 2015; 6:334-43; PMID:26335399; http://dx.doi.org/10.1016/j.redox.2015.08.00910.1016/j.redox.2015.08.009
   PubMed Web of Science ®Google Scholar
• Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, et al. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget 2016; 7:52993-3004; PMID:27367029; http://dx.doi.org/10.18632/oncotarget.10323
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri250610.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138:105-15; PMID:23216602; http://dx.doi.org/10.1111/imm.1203610.1111/imm.12036
   PubMed Web of Science ®Google Scholar
• Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 2012; 188:5365-76; http://dx.doi.org/10.4049/jimmunol.110355310.4049/jimmunol.1103553
   PubMed Web of Science ®Google Scholar
• Ito H, Ando T, Seishima M. Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model. Oncotarget 2015; 6:41863-74; PMID:26496031
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68-77; PMID:20028852; http://dx.doi.org/10.1158/0008-5472.CAN-09-258710.1158/0008-5472.CAN-09-2587
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439-49; PMID:18593947; http://dx.doi.org/10.1158/0008-5472.CAN-07-662110.1158/0008-5472.CAN-07-6621
   PubMed Web of Science ®Google Scholar
• Jayaraman P, Alfarano MG, Svider PF, Parikh F, Lu G, Kidwai S, Xiong H, Sikora AG. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFbeta1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity. Clin Cancer Res 2014; 20:6439-51; PMID:25278453; http://dx.doi.org/10.1158/1078-0432.CCR-13-340910.1158/1078-0432.CCR-13-3409
   PubMed Web of Science ®Google Scholar
• Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, Voelkel-Johnson C. Efficacy of adoptive T-cell therapy is improved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death. Cancer Res 2016; 76:6006-16; PMID:27742673; http://dx.doi.org/10.1158/0008-5472.CAN-16-058710.1158/0008-5472.CAN-16-0587
   PubMed Web of Science ®Google Scholar
• Majano PL, Medina J, Zubía I, Sunyer L, Lara-Pezzi E, Maldonado-Rodríguez A, López-Cabrera M, Moreno-Otero R. N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol 2004; 40:632-7; PMID:15030979; http://dx.doi.org/10.1016/j.jhep.2003.12.00910.1016/j.jhep.2003.12.009
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j.cell.2010.03.01410.1016/j.cell.2010.03.014
   PubMed Web of Science ®Google Scholar
• Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol 2015; 33:643-75; PMID:25861979; http://dx.doi.org/10.1146/annurev-immunol-032414-11222010.1146/annurev-immunol-032414-112220
   PubMed Web of Science ®Google Scholar
• Lu G, Zhang R, Geng S, Peng L, Jayaraman P, Chen C, Xu F, Yang J, Li Q, Zheng H, et al. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. Nat Communicat 2015; 6:6676; PMID:25813085; http://dx.doi.org/10.1038/ncomms767610.1038/ncomms7676
   PubMed Web of Science ®Google Scholar
• Ito H, Ando T, Ogiso H, Arioka Y, Seishima M. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice. Cancer Immunol Immunoth 2015; 64:429-36; PMID:25567751; http://dx.doi.org/10.1007/s00262-014-1644-610.1007/s00262-014-1644-6
   PubMed Web of Science ®Google Scholar
• Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 2016; 22:3849-59; PMID:26957560; http://dx.doi.org/10.1158/1078-0432.CCR-15-191210.1158/1078-0432.CCR-15-1912
   PubMed Web of Science ®Google Scholar
• De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 2016; 539:443-7; PMID:27828943; http://dx.doi.org/10.1038/nature2055410.1038/nature20554
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74:5057-69; PMID:25082815; http://dx.doi.org/10.1158/0008-5472.CAN-13-372310.1158/0008-5472.CAN-13-3723
   PubMed Web of Science ®Google Scholar
• Green KA, Wang L, Noelle RJ, Green WR. Selective involvement of the checkpoint regulator VISTA in suppression of B-cell, but not T-cell, responsiveness by monocytic myeloid-derived suppressor cells from mice infected with an immunodeficiency-causing retrovirus. J Virol 2015; 89:9693-8; PMID:26157131; http://dx.doi.org/10.1128/JVI.00888-1510.1128/JVI.00888-15
   PubMed Web of Science ®Google Scholar